28137551|t|Bromocriptine Induces Autophagy -Dependent Cell Death in Pituitary Adenomas
28137551|a|Bromocriptine (BRC) is effective in patients with prolactinoma. However, the cytotoxic mechanism of BRC remains unknown. Slices for immunohistochemical pathology were randomly selected from 37 paraffin-embedded prolactinoma tissue sections. LC3 was detected by immunohistochemistry. GH3 and MMQ cells were treated by BRC and/or rapamycin (RAPA). Cell viability and the cell cycle were measured by CCK-8 and flow cytometry, respectively. Enzyme-linked immunosorbent assay measured prolactin secretion. Protein expression was detected by Western blot or immunofluorescence. LC3 was significantly expressed in prolactinoma in which patients were treated exclusively with BRC. LC3 expression was negative in normal tissues and prolactinoma in which patients were not treated with BRC. Treatment with 60 μM BRC for 24 hours induced cell death in MMQ cells by up to 50%. However, 110 μM BRC was required to produce a similar effect in GH3 cells. The cell cycle was arrested at the G0 - G1 phase and S phase. As the concentration and time increased, the conversion ratio of LC3-I to LC3-II increased and prolactin secretion decreased. In addition, Bcl-2 and BAX expression was decreased. The cell viability, prolactin level, and G0-G1 cells are similar in MMQ cells treated with RAPA and a low concentration of BRC and MMQ cells treated with a high concentration of BRC. Compared with the effects of a high concentration of BRC, treatment with RAPA and a low concentration of BRC effectively increase the conversion rate of LC3-I to LC3-II. BRC - treated pituitary adenoma cells mainly underwent autophagic cell death rather than apoptosis.
28137551	0	13	Bromocriptine	T103	UMLS:C0006230
28137551	22	31	Autophagy	T038	UMLS:C0004391
28137551	43	53	Cell Death	T038	UMLS:C0007587
28137551	57	75	Pituitary Adenomas	T038	UMLS:C0032000
28137551	76	89	Bromocriptine	T103	UMLS:C0006230
28137551	91	94	BRC	T103	UMLS:C0006230
28137551	126	138	prolactinoma	T038	UMLS:C0033375
28137551	176	179	BRC	T103	UMLS:C0006230
28137551	228	237	pathology	T091	UMLS:C0030664
28137551	269	306	paraffin-embedded prolactinoma tissue	T017	UMLS:C1519524
28137551	317	320	LC3	T103	UMLS:C2003747
28137551	325	333	detected	T033	UMLS:C0442726
28137551	337	357	immunohistochemistry	T058	UMLS:C0021044
28137551	359	362	GH3	T017	UMLS:C0229535
28137551	367	376	MMQ cells	T017	UMLS:C0229535
28137551	393	396	BRC	T103	UMLS:C0006230
28137551	404	413	rapamycin	T103	UMLS:C0072980
28137551	415	419	RAPA	T103	UMLS:C0072980
28137551	422	436	Cell viability	T038	UMLS:C0007620
28137551	445	455	cell cycle	T038	UMLS:C0007586
28137551	473	478	CCK-8	T062	UMLS:C2986858
28137551	483	497	flow cytometry	T058	UMLS:C0016263
28137551	513	546	Enzyme-linked immunosorbent assay	T058	UMLS:C0014441
28137551	556	575	prolactin secretion	T038	UMLS:C2611224
28137551	577	595	Protein expression	T038	UMLS:C1171362
28137551	600	608	detected	T033	UMLS:C0442726
28137551	612	624	Western blot	T058	UMLS:C0005863
28137551	628	646	immunofluorescence	T058	UMLS:C0079603
28137551	648	651	LC3	T103	UMLS:C2003747
28137551	670	679	expressed	T038	UMLS:C1171362
28137551	683	695	prolactinoma	T038	UMLS:C0033375
28137551	744	747	BRC	T103	UMLS:C0006230
28137551	749	763	LC3 expression	T038	UMLS:C1171362
28137551	768	776	negative	T033	UMLS:C0205160
28137551	787	794	tissues	T017	UMLS:C0040300
28137551	799	811	prolactinoma	T038	UMLS:C0033375
28137551	839	851	treated with	T058	UMLS:C0332293
28137551	852	855	BRC	T103	UMLS:C0006230
28137551	857	866	Treatment	T058	UMLS:C0087111
28137551	878	881	BRC	T103	UMLS:C0006230
28137551	903	913	cell death	T038	UMLS:C0007587
28137551	917	926	MMQ cells	T017	UMLS:C0229535
28137551	957	960	BRC	T103	UMLS:C0006230
28137551	1005	1014	GH3 cells	T017	UMLS:C0229535
28137551	1020	1030	cell cycle	T038	UMLS:C0007586
28137551	1035	1043	arrested	T038	UMLS:C1155873
28137551	1051	1053	G0	T038	UMLS:C0079394
28137551	1056	1064	G1 phase	T038	UMLS:C1155840
28137551	1069	1076	S phase	T038	UMLS:C1155869
28137551	1143	1148	LC3-I	T103	UMLS:C2003747
28137551	1152	1158	LC3-II	T103	UMLS:C2003747
28137551	1173	1192	prolactin secretion	T038	UMLS:C2611224
28137551	1217	1222	Bcl-2	T103	UMLS:C0293686
28137551	1227	1230	BAX	T103	UMLS:C0219474
28137551	1231	1241	expression	T038	UMLS:C1171362
28137551	1261	1275	cell viability	T038	UMLS:C0007620
28137551	1277	1292	prolactin level	T033	UMLS:C0428411
28137551	1325	1334	MMQ cells	T017	UMLS:C0229535
28137551	1335	1347	treated with	T058	UMLS:C0332293
28137551	1348	1352	RAPA	T103	UMLS:C0072980
28137551	1380	1383	BRC	T103	UMLS:C0006230
28137551	1388	1397	MMQ cells	T017	UMLS:C0229535
28137551	1398	1410	treated with	T058	UMLS:C0332293
28137551	1435	1438	BRC	T103	UMLS:C0006230
28137551	1493	1496	BRC	T103	UMLS:C0006230
28137551	1498	1507	treatment	T058	UMLS:C0087111
28137551	1513	1517	RAPA	T103	UMLS:C0072980
28137551	1545	1548	BRC	T103	UMLS:C0006230
28137551	1593	1598	LC3-I	T103	UMLS:C2003747
28137551	1602	1608	LC3-II	T103	UMLS:C2003747
28137551	1610	1613	BRC	T103	UMLS:C0006230
28137551	1624	1641	pituitary adenoma	T038	UMLS:C0032000
28137551	1642	1647	cells	T017	UMLS:C0334227
28137551	1665	1675	autophagic	T038	UMLS:C0004391
28137551	1676	1686	cell death	T038	UMLS:C0007587
28137551	1699	1708	apoptosis	T038	UMLS:C0162638